Atea Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVIR research report →
Companyateapharma.com
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19.
- CEO
- Jean-Pierre Sommadossi
- IPO
- 2020
- Employees
- 56
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $335.71M
- P/E
- -1.96
- P/S
- 0.00
- P/B
- 1.42
- EV/EBITDA
- -1.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.01%
- ROIC
- -78.11%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-158,349,000 · 5.96%
- EPS
- $-1.94 · 3.00%
- Op Income
- $-180,887,000
- FCF YoY
- 2.56%
Performance & Tape
- 52W High
- $6.45
- 52W Low
- $2.78
- 50D MA
- $5.52
- 200D MA
- $4.02
- Beta
- 0.38
- Avg Volume
- 450.45K
Get TickerSpark's AI analysis on AVIR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 26 | Corcoran Andrea | other | 60,000 |
| Mar 11, 26 | Corcoran Andrea | other | 60,000 |
| Jan 31, 26 | Horga Maria Arantxa | other | 173,500 |
| Jan 31, 26 | Horga Maria Arantxa | other | 51,283 |
| Jan 31, 26 | Horga Maria Arantxa | other | 16,073 |
| Jan 31, 26 | Horga Maria Arantxa | other | 9,750 |
| Jan 31, 26 | Vavricka John | other | 119,520 |
| Jan 31, 26 | Vavricka John | other | 42,083 |
| Jan 31, 26 | Vavricka John | other | 11,570 |
| Jan 31, 26 | Vavricka John | other | 8,750 |
Our AVIR Coverage
We haven't published any research on AVIR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVIR Report →